Survodutide — pharmacology
Molecular targets, mechanism of action, pharmacokinetics and interactions as characterised in humans.
§2Pharmacology
§2.1Molecular targets
Table 2. Molecular targets recorded for Survodutide, with the character of the interaction and the potency where the Institute holds it.
| Target | Interaction | Note |
|---|---|---|
| Glucagon receptor (GCGR) | Agonist | Higher relative potency than in retatrutide |
| GLP-1 receptor (GLP1R) | Agonist | Balanced against the glucagon arm |
§2.2Mechanism of action
Glucagon receptor agonism increases hepatic fatty-acid oxidation, resting energy expenditure and hepatic lipid clearance; GLP-1 receptor agonism supplies appetite suppression and offsets the glycaemic consequences of glucagon signalling. The combination is of particular interest in steatohepatitis, where a direct hepatic mechanism is mechanistically attractive rather than purely weight-mediated.[1,2]
§2.3Pharmacokinetics
- Terminal half-life
- ≈6 days
- Time to maximum concentration
- approximately 24–48 h
- Volume of distribution
- not published
- Plasma protein binding
- high
- Clearance
- not published
- Bioavailability
- not published
Assumed proteolytic with beta-oxidation of the diacid.
§2.4Interactions
- Not characterised
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology 2024;12(3):162–173. doi:10.1016/S2213-8587(23)00356-X · PMID 38330977
- Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM. A phase 2 randomized trial of survodutide in MASH and fibrosis. New England Journal of Medicine 2024;391(4):311–319. doi:10.1056/NEJMoa2401755 · PMID 38847460
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.